Newly Powerful Sarms Steroid Powder Gw 0742

We specialize in raw steroid powder, premade oils, sarms and peptides, We offer USA domestic shipping, safe and fast shipping to Canada, UK, Netherlands, Belarus, Russia, Greece, Bulgaria , Australia, Spain, France, Sweden, Colombia, South Africa,
Malaysia, Thailand, Singapore, Japan, Korea, Portugal, Poland, Denmark, Italy, Ukraine, Germany, etc. Moreover, we also have the reshipment policy to guarantee your right. No fear of seizure, just peace of mind with the best offer. Pls contatc me for list.

Wickr: puresteroid
Whatsapp: +8618872220826
Email: selina@ycgmp.com

Newly Powerful Sarms Steroid Powder Gw 0742 For Obesity Treatment

GW0742 Descrption

GW0742, also known as GW610742, is a PPAR agonist. GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons. GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. GW0742 has direct protective effects on right heart hypertrophy.GW0742 may enhance lipid metabolism in heart both in vivo and in vitro.

GW0742 Application

GW 0742 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue , and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome , most likely by stimulating fatty acid oxidation .

GW0742 has been proposed as a potential treatment for obesity and related conditions , especially when used in conjunction with a synergistic compound AICAR , as the combination has been shown to significantly increase exercise endurance in human.

How GW0742 Works

The highest antagonist activity for GW0742 was found for VDR and the androgen receptor (AR). Surprisingly, GW0742 behaved as PPAR agonist/antagonist activating transcription at lower concentration and inhibiting this effect at higher concentrations. A unique spectroscopic property of GW0742 was identified as well. In the presence of rhodamine-derived molecules, GW0742+ increased fluorescence intensity and fluorescence polarization at an excitation wavelength of 595 nm and emission wavelength of 615 nm in a dose dependent manner.

The GW0742-inhibited NR-coactivator binding resulted in a reduced expression of five different NR target genes in LNCaP cells in the presence of agonist. Especially VDR target genes CYP24A1, IGFBP-3 and TRPV6 were negatively regulated by GW0742. GW0742 is the first VDR ligand inhibitor lacking the secosteroid structure of VDR ligand antagonists. Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.